Many biomedical startups discover that proving an idea works is only the beginning.

Clinical trials, regulatory studies, manufacturing scale-up and validation can require millions of dollars after a standard Phase II SBIR or STTR grant ends.

The NIH SBIR Phase IIB Strategic Breakthrough Award, PA-27-101, is designed specifically for this funding gap.

The programme provides additional non-dilutive federal funding to previous NIH Phase II recipients that have strong commercial potential but still require significant late-stage research and development before commercialisation.

The next submission dates are January 5 and April 5, 2027, and the parent opportunity remains available through April 2029.

What Is the Phase IIB Strategic Breakthrough Award?

NIH describes the gap between Phase II and full commercialisation as the biomedical “Valley of Death.”

A technology may have excellent scientific evidence but still require expensive clinical, manufacturing or regulatory work before investors, strategic partners or customers are willing to commit.

Phase IIB provides a second Phase II-level award to help bridge that gap.

It is particularly relevant for technologies involving:

• Regulatory approval;
• Complex manufacturing;
• Clinical validation;
• Pivotal studies;
• Product optimisation;
• Small or specialised medical markets.

How Much Funding Is Available?

The parent NOFO allows total federal support of up to $30 million, although participating NIH institutes set substantially lower normal limits for most projects.

Current examples include:

• National Cancer Institute: up to $15 million;
• NHLBI: up to $4.5 million;
• NIA: up to $3 million;
• NIAID: up to $3 million;
• NIDDK: up to $3 million;
• NINDS: up to $3 million.

The project period may extend for up to four years.

The 100% Matching Requirement

This is the feature founders must understand before spending months preparing an application.

The Phase IIB Strategic Breakthrough Award requires the company to demonstrate at least 100% matching funding.

If a company requests $3 million from NIH, it must demonstrate at least another $3 million in qualifying matching funding.

The match may come from new private capital, new funding from another government programme other than SBIR/STTR Phase I or II, or a combination of the two.

Letters documenting commitment of the matching capital should accompany the application, and additional proof may be requested during the Just-in-Time process.

This requirement is intended to demonstrate genuine external confidence in the technology’s commercial prospects.

Who Can Apply?

Only eligible U.S. small business concerns with a previous SBIR or STTR Phase II award can apply.

The applicant should normally submit the Phase IIB application within the first six applicable due dates after the end of its Phase II budget period.

Only one Phase IIB Strategic Breakthrough Award is allowed for each project.

This means an early-stage company seeking its first NIH grant should apply through Phase I or another appropriate mechanism instead.

What Makes an Application Competitive?

Commercial potential is central.

A strong application should show that the previous Phase II produced meaningful technical results and that the remaining work has a defined path towards commercialisation.

Founders should present:

• Phase II results;
• Current product maturity;
• Customer and market evidence;
• Intellectual-property protection;
• Regulatory strategy;
• Manufacturing strategy;
• Competition;
• Third-party funding commitments;
• Commercialisation milestones.

The business should explain what specific risk the Phase IIB funding will remove.

Phase IIB or CRP?

Companies with strong matching investors and a substantial late-stage R&D programme may be suitable for Phase IIB.

Companies that need significant outsourced development work but do not have matching capital should also investigate the Commercialization Readiness Pilot.

NIH explicitly encourages companies to speak with programme staff before selecting between the two routes.

Application Deadline

The next standard deadline is January 5, 2027, followed by April 5, 2027 and future September, January and April cycles through 2029.

Applications are due at 5:00pm local time of the applicant organisation.

View the official Phase IIB Strategic Breakthrough Award PA-27-101

For a mature biomedical startup already backed by external investors, Phase IIB can provide the non-dilutive capital needed to move from promising research to a genuinely commercial product.